1 pending office actions • 0 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Corvus Pharmaceuticals Inc. has 1 pending office action. The matter is assigned to 1 examiner, and the profile reports 0 distinct art units.
WHITE, DAWANNA SHAR-DAY is the listed examiner and has 1 pending matter. Counsel should focus on the single examination record and confirm how the application is being handled before developing a broader prosecution plan.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| WHITE, DAWANNA SHAR-DAY | 1 | 63.3% | +24.0% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18852735 | ITK INHIBITORS FOR INCREASING TH1 CELL ACTIVITY | WHITE, DAWANNA SHAR-DAY | — |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18852735 | ITK INHIBITORS FOR INCREASING TH1 CELL ACTIVITY | WHITE, DAWANNA SHAR-DAY | — | §103Other | Non-Final OA | — | Pending | Sep 30, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialCorvus Pharmaceuticals Inc. has 1 pending office actions as of November 2026, spread across 0 art units and 1 examiners.
Dawanna Shar-Day White has the most, with 1 of Corvus Pharmaceuticals Inc.'s pending office actions.